We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
-5.51%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$285M
AUM Growth
-$94.6M
(-25%)
Cap. Flow
-$78.6M
Cap. Flow
% of AUM
-27.58%
Top 10 Holdings %
Top 10 Hldgs %
56.44%
Holding
82
New
19
Increased
11
Reduced
16
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$17M |
| 2 |
Qiagen
QGEN
|
+$15.8M |
| 3 |
Icon
ICLR
|
+$11.1M |
| 4 |
Zoetis
ZTS
|
+$7.11M |
| 5 |
Baxter International
BAX
|
+$6.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$15.9M |
| 2 |
Orthofix Medical
OFIX
|
+$14.2M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$14.2M |
| 4 |
Centene
CNC
|
+$12.5M |
| 5 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$9.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Qiagen
QGEN
$8.54B
| $18.8M | 6.59% |
375,545
+323,058
| +616% | +$15.8M |
|
|
2
Boston Scientific
BSX
$69.5B
| $15.6M | 5.47% |
+418,165
| New | +$17M |
|
3
Avantor
AVTR
$9.32B
| $14M | 4.92% |
450,821
+164,920
| +58% | +$5.15M |
|
4
Humana
HUM
$43.7B
| $12.7M | 4.45% |
27,106
-2,014
| -7% | -$896K |
|
|
5
Icon
ICLR
$12.6B
| $10.8M | 3.78% |
+49,718
| New | +$11.1M |
|
6
Cigna
CI
$73.7B
| $10.6M | 3.73% |
40,372
+11,655
| +41% | +$3M |
|
7
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| $9.77M | 3.43% |
25,900
-76,000
| -75% | -$31.1M |
|
8
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| $9.36M | 3.28% |
126,000
| – | – |
|
|
HOLX
9
DELISTED
Hologic
HOLX
| $8.85M | 3.1% |
127,656
+4,032
| +3% | +$299K |
|
10
Labcorp
LH
$25B
| $8.14M | 2.85% |
40,412
-30,917
| -43% | -$6.59M |
|
11
Elutia
ELUT
$37.9M
| $8.01M | 2.81% |
1,133,183
+23,704
| +2% | +$153K |
|
12
Bio-Rad Laboratories Class A
BIO
$8.71B
| $7.93M | 2.78% |
16,028
-1,123
| -7% | -$585K |
|
|
13
Zoetis
ZTS
$32.4B
| $7.07M | 2.48% |
+41,100
| New | +$7.11M |
|
14
Cartesian Therapeutics
RNAC
$229M
| $6.04M | 2.12% |
153,721
+38,656
| +34% | +$1.15M |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.82M | 2.04% |
+32,871
| New | +$4.74M |
|
|
16
Centene
CNC
$30.7B
| $5.78M | 2.03% |
68,305
-149,930
| -69% | -$12.5M |
|
|
17
Baxter International
BAX
$13.5B
| $5.77M | 2.02% |
+89,863
| New | +$6.52M |
|
18
SI-BONE Inc
SIBN
$788M
| $5.68M | 1.99% |
430,159
+16,789
| +4% | +$280K |
|
19
McKesson
MCK
$100B
| $5.21M | 1.83% |
15,984
-13,184
| -45% | -$4.22M |
|
20
PUT
Invesco QQQ Trust
QQQ
$453B
| $3.73M | 1.31% |
+13,300
| New | +$4.13M |
|
21
Teva Pharmaceuticals
TEVA
$40.8B
| $3.46M | 1.21% |
+459,829
| New | +$4.01M |
|
|
ADAP
22
DELISTED
Adaptimmune Therapeutics
ADAP
| $3.1M | 1.09% |
1,824,065
-336,825
| -16% | -$579K |
|
23
Ocular Therapeutix
OCUL
$1.79B
| $3.06M | 1.07% |
760,228
-163,735
| -18% | -$619K |
|
|
LKFT
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
| $2.87M | 1.01% |
51,410
-990
| -2% | -$58.7K |
|
25
Insmed
INSM
$21.4B
| $2.8M | 0.98% |
142,071
-23,209
| -14% | -$486K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Endurant Capital Management held 82 positions worth $285M, down 25% from $380M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Endurant Capital Management withdrew a net $78.6M in Q2 2022, closing 32 positions and reducing 16 holdings. Its most notable exit was AstraZeneca, an estimated $15.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 70% a quarter earlier.
Against the trend, Endurant Capital Management opened a new position in Boston Scientific worth $15.6M.
- Endurant Capital Management's largest Q2 2022 buy was Boston Scientific: 418,165 shares worth $15.6M.
- Endurant Capital Management added most to Qiagen in Q2 2022, an estimated $15.8M increase.
- Endurant Capital Management's biggest Q2 2022 reduction was Centene, cutting an estimated $12.5M.
- Endurant Capital Management fully exited AstraZeneca in Q2 2022, selling an estimated $15.9M.
- Endurant Capital Management's ten largest holdings make up 56% of its $285M portfolio in Q2 2022.
- Endurant Capital Management opened 19 new positions and closed 32 in Q2 2022.
- Endurant Capital Management's portfolio value fell 25% quarter-over-quarter to $285M.
Based on Endurant Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.